List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 20 studies with search of:   "paroxysmal nocturnal hemoglobinuria"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Role of Prion Protein in Human Hematopoietic Stem Cells
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention:
2 Recruiting Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
Conditions: Allogeneic Stem Cell Transplant;   Leukemia;   Non-Hodgkins;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Drug: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant;   Drug: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
3 Completed Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria
Intervention:
4 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: Eculizumab
5 Completed Eculizumab to Treat Hemolytic Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Intervention: Drug: Eculizumab
6 Completed Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
Conditions: Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Paroxysmal Nocturnal Hemoglobinuria;   Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Drug: Systematic chemotherapy and antibodies;   Procedure: Allogeneic stem cell transplantation;   Device: Miltenyi CliniMACS
7 Completed Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Secondary AML;   Myelodysplastic Syndrome (MDS);   Secondary MDS;   Chronic Myeloid Leukemia;   Juvenile Myelomonocytic Leukemia (JMML);   Paroxysmal Nocturnal Hemoglobinuria (PNH);   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Procedure: Stem Cell Transplantation;   Device: Miltenyi Biotec CliniMACS;   Drug: Systemic chemotherapy and antibodies
8 Completed Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Leukemia
Intervention: Drug: eculizumab
9 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Intervention: Drug: Eculizumab
10 Active, not recruiting Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Conditions: Aplastic Anemia;   Paroxysmal Hemoglobinuria, Nocturnal
Interventions: Drug: cyclophosphamide;   Drug: filgrastim
11 Completed Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Interventions: Drug: eculizumab;   Drug: eculizumab
12 Approved for marketing The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
13 Completed Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
14 Completed Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
15 Active, not recruiting T-Cell Depletion, Donor Stem Cell Transplant, and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
Conditions: Cancer-Related Problem/Condition;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous/Nonmalignant Condition
Interventions: Drug: cyclophosphamide;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood lymphocyte therapy;   Procedure: peripheral blood stem cell transplantation;   Procedure: total-body irradiation
16 Active, not recruiting Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: total-body irradiation
17 Recruiting Identifying Characteristics of Bone Marrow Failure Syndromes
Conditions: Bone Marrow Failure Syndromes;   Anemia, Aplastic;   Myelodysplastic Syndromes;   Hemoglobinuria, Paroxysmal;   Red-Cell Aplasia, Pure;   Purpura, Thrombocytopenic;   Leukemia, Lymphocytic
Intervention:
18 Recruiting Natural History of Sickle Cell Disease and Other Hemolytic Disorders
Conditions: Hemoglobin SC Disease;   Hematologic Diseases;   Sickle Cell Anemia;   Hemolytic Anemia
Intervention:
19 Recruiting Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Precancerous/Nonmalignant Condition
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
20 Recruiting Clofarabine, Melphalan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Diseases
Conditions: Cancer-Related Problem/Condition;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition
Interventions: Drug: alemtuzumab;   Drug: clofarabine;   Drug: melphalan;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: gene expression analysis;   Procedure: high performance liquid chromatography;   Procedure: laboratory biomarker analysis;   Procedure: peripheral blood stem cell transplantation;   Procedure: pharmacological study;   Procedure: polymorphism analysis;   Procedure: reverse transcriptase-polymerase chain reaction

  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services